← Back to Search

Antiplatelet Agent

Low Molecular Weight Heparin (LMWH)-Enoxaparin for Blood Clot (PREVENT CLOT Trial)

Phase 3
Waitlist Available
Led By Robert O'Toole, MD
Research Sponsored by Major Extremity Trauma Research Consortium
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

Summary

The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH) (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.

Eligible Conditions
  • Blood Clot
  • Trauma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With All-cause Mortality
Secondary outcome measures
Number of Participants With Cause-specific Death

Trial Design

2Treatment groups
Active Control
Group I: Low Molecular Weight Heparin (LMWH)-EnoxaparinActive Control1 Intervention
Injection of 30 mg enoxaparin, twice a day via injection
Group II: Acetylsalicylic acid (ASA)-AspirinActive Control1 Intervention
Enteral ingestion or administration of 81 mg ASA, twice a day

Find a Location

Who is running the clinical trial?

Major Extremity Trauma Research ConsortiumLead Sponsor
31 Previous Clinical Trials
15,032 Total Patients Enrolled
Patient-Centered Outcomes Research InstituteOTHER
568 Previous Clinical Trials
27,236,985 Total Patients Enrolled
Katherine Frey, PhD, MPH, RNStudy DirectorJohns Hopkins Bloomberg School of Public Health
~1491 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top